Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced leadership participation in multiple ophthalmology and industry conferences in February 2026, presenting clinical and manufacturing updates.

Events include CCOI (Feb 3-4, Hong Kong), APAO (Feb 5-8, Hong Kong), Advanced Therapies Week (Feb 11, San Diego) and Macula Society (Feb 27, San Diego).

News Market Reaction

+0.43%

1 alert

+0.43% News Effect

+$726K Valuation Impact

$170M Market Cap

0.0x Rel. Volume

On the day this news was published, IRD gained 0.43%, reflecting a mild positive market reaction. This price movement added approximately $726K to the company's valuation, bringing the market cap to $170M at that time.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.

Collaborative Community on Ophthalmic Innovation (CCOI)

• Topic: Opus Genetics leadership will participate in discussions focused on emerging treatment approaches and clinical insights in retinal disease.
• Date: February 3-4, 2026
• Location: Hong Kong
  

Asia-Pacific Academy of Ophthalmology Congress (APAO)

• Topic: The Company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders.
• Date: February 5-8, 2026
• Location: Hong Kong
  

Advanced Therapies Week Conference

• Title: Building scalable viral vector manufacturing models
• Speaker: Chris Ernst, Chief Technology Officer, Opus Genetics
• Date/Time: February 11, 2026, 10:30 – 11:00 AM PT
• Location: San Diego, CA

The Macula Society Annual Meeting

• Title: Preliminary Results from Sentinel Patient in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
• Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute
• Date/Time: February 27, 2026, 7:15 – 7:20 AM PT
• Location: San Diego, CA
  

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

What will Opus Genetics (IRD) present at the Macula Society Annual Meeting on February 27, 2026?

Opus Genetics will present preliminary Phase 1b/2a results for OPGx-BEST1 targeting BVMD and ARB. According to the company, Mark Pennesi, M.D., Ph.D., will deliver a brief presentation summarizing sentinel-patient safety and early clinical observations from the study.

When and where is Opus Genetics (IRD) speaking about viral vector manufacturing during Advanced Therapies Week?

Opus Genetics will speak on scalable viral vector manufacturing on February 11, 2026 at 10:30 AM PT in San Diego. According to the company, CTO Chris Ernst will discuss building manufacturing models relevant to gene therapy scale-up and production.

Which conferences will Opus Genetics (IRD) leadership attend in Hong Kong in early February 2026?

Opus Genetics leadership will attend CCOI on February 3-4 and APAO on February 5-8 in Hong Kong. According to the company, sessions will cover emerging retinal treatment approaches and global gene-therapy strategies for inherited retinal disorders.

How might Opus Genetics' (IRD) conference presentations affect investor awareness of its clinical programs?

Conference presentations may increase visibility for Opus Genetics' clinical programs among specialists and investors. According to the company, presenting preliminary clinical data and manufacturing plans aims to inform clinicians, potential partners, and the investor community about program progress.

Who are the named Opus Genetics (IRD) presenters at February 2026 events and what are their topics?

Named presenters include CTO Chris Ernst on scalable viral vector manufacturing and Mark Pennesi, M.D., Ph.D., on OPGx-BEST1 preliminary clinical results. According to the company, topics span manufacturing strategies and early clinical findings in inherited retinal disease therapy development.